It has been around a year since Beam Therapeutics slashed its headcount and R&D programmes to focus mainly on a sickle cell disease candidate – and the biotech has now revealed the first data with the ...
Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...
Looking for WordPress alternatives that fit your stack? Compare builders, ecommerce platforms, headless CMS, and site ...
With the price of pitching sky-high and pitchers often hurt, a wave of mid-career imports have arrived in MLB, touting big ...
Traditional threat modeling too often comes late to the party, or sometimes not at all. In addition, creating manual data flows and reports can be extremely time-consuming. The goal of pytm is to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback